Antiplatelet therapy with either aspirin and P2Y12 inhibition was ineffective at improving death and organ support free days in critically ill COVID-19 patients, latest results from REMAP-CAP show.
The findings are based on an analysis of 1467 critically ill patients and are yet to be peer reviewed and published. Previously, aspirin and P2Y12 inhibition had been proven to be equivalent in the trial.
Another important finding, in line with data from Recovery trial that anti-platelet agents have no benefit in the management of #COVID19 pneumonia https://t.co/EKkTFunXaU
— Beverley Hunt (@bhwords) June 29, 2021
The results highlight that the probability of futility of antiplatelet therapy (defined as an odds ratio of < 1.2) was 98%, well above the platform threshold of 95%.
The odds ratio for improving the primary outcome of death and organ support free days was 0.99 (95% Credible Interval 0.82 – 1.19) for these drugs, compared to no antiplatelet therapy.